Optibiotix Health Share Discussion Threads

[bobdown2] 03/11/2016 14:22

I look foward to Marnewton,s post and try to learn from them. The other one has been filtered since I fell out with her on my first day here..

[neftanikoff] 03/11/2016 14:18

Indeed, it is good to have people posting on here with some knowledge of charting, even if is only aim. i mean who would you rather receive a post from out of these 2 , marnewton or the very critical judijudi. This is a no brainer as the former adds something to the thread and the latter does not. I hope the former is not put off from posting his chart views on this share as they very well received.

[marnewton] 03/11/2016 14:14

Thanks for all the kind words chaps...and the green thumbs.

I'd better be right this time then!

I do think OPTI is finally on the turn after six months of downward drift - BUT - we haven't had confirmation of a trend change just yet.

Cheers,

Martin

[lodger] 03/11/2016 13:57

I bought some more earlier today, the chart feels like it's about to breakout.

[parob] 03/11/2016 12:57

Transcript from the Directors Talk Interview:Q&A with Stephen O'Hara Chief Executive Officer at OptiBiotix Health PLC (LON:OPTI)OptiBiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O'Hara caught up with DirectorsTalk to discuss their recent scientific and commercial update Q1: Now Stephen you recently put out a scientific and commercial update, first off can you tell us a bit more about the scientific update?A1: OptiBiotix has made a lot of progress in the last 6 months and is presenting this at a major European microbiome summit later on this week and these developments have the potential to significantly increase shareholder value and hence we felt the reason for the RNS. Let me try to give an oversight in terms of the significance of these findings for investors:Most people are aware that in the last 2-3 years there's been a growing understanding of the role of the microbiome in human health and this has led to many microbiome companies for example 4D Pharma having valuations in excess of half a billion pounds. Now these valuations reflect the size of the microbiome opportunity estimated to be in the region of a trillion dollars, however no-one in all that time has demonstrated an ability to change the microbiome in a way that improves health, Optibiotix's research over the last 6 months has changed all of that.We not only demonstrated that we can change the microbiome but we can do this in a very targeted way down to particular bacterial species so to use a metaphor it's bit like being able to increase the growth rate of a particular species of tree in a forest which subsequently grows quicker than the other trees and dominates the forest. More importantly we have demonstrated about targeting a particular species for example a species that helps in producing cholesterol we can enhance that benefit so for example in the case of our cholesterol reducing strain we've been able to show a three-fold increase in the strain's ability to lower cholesterol. So if you believe, as many health commentators do, that the microbiome will have a major impact on a prevention management of treatment of human disease in the future, having the ability to alter particular species, particular components of a patient's microbiome, is a major step forward.Q2: And on the commercial side, what can you tell me there?A2: The commercial update was intended to provide investors with an update on the commercialisation of both our weight management product and our cholesterol product.First, let's look at the weight management product which has been a great success in terms of sales and also in terms of customer feedback with some great reviews on Amazon and in our short survey. We now have over 800 online customers, so remember we only launched this in July, we haven't advertised this at all so this is all word of mouth, so 800 online customers in that period of time and some great customer reviews. The product's on sale in wholefoods and they've reordered and restocked and we now export into Iceland, that's the country as opposed to the shop, so sales are steadily growing, they're currently at around 25-27K per month and this makes this part of the company a profitable business. As we move forward what we intend to do is to increase the number of sales outlets selling the GoFigure products and to increase the number of applications that contain OptiBiotix SlimBiome ingredients, this is the ingredient which is a component part of GoFigure which is hunger-free dieting. I'm sure investors will see that this area alone, just the weight management area, has the potential of a very very strong sales growth over the next few years if it can take the years' success and grow that within the UK and then take that to other countries and international it.In terms of the cholesterol product, the RNS indicates that we've been building the science, we've been building the IP, we've developed a range of different formulations and most importantly we've been working with partners who have the necessary capability in terms of manufacturing and distribution and sales infrastructure to support a product launch in 2017. We see our strain, which we have now trademarked as LP-LDL, as very much the intel inside a range of products for cardio-vascular health across both consumer health and pharma and whilst time-consuming, building multiple deals helps diversify investor risk and if successful will give a far greater shareholder return.Q3: So how does this fit into OptiBiotix's overall strategy?A3: For anyone that has heard me speak over the last 2 years will know that when I founded OptiBiotix I structured the company in a way which created multiple opportunities, I didn't want a single technology and single product company because if things go wrong then you have nowhere to go. So the strategy that I developed diversifies both development and investor risk and creates the potential for multiple revenue streams and investors now are starting to see the fruits of this strategy. To recap in terms of where we are:We've got products ready on the market, that's the GoFigure products containing the SlimBiome, and as I said earlier they've got great customer reviews, good market tractions and we're looking to grow them out into other markets, both nationally and internationally.We also announced in this RNS this launch of our cardio-vascular product range in the spring of 2017 so we've got revenues now with one product, revenues to come in the future with the cardio-vascular product.We've got the cost of our development in our sugar products largely covered by partnering deals and they themselves will develop into royalty streams in the future.So something for now, something for the near future and something for a bit further down the line and despite all of this activity over the last 6 months or so, since we reported our interims, we still have £3.5 million in the bank. So in summary we have a great solid financial base, we have products on the market now and we have a product launch planned for next year and then a pipeline of really good science creating new opportunities for the future. We're encouraged by all of this, we think the future's bright for OptiBiotix Health.

[the guardian] 03/11/2016 12:04

As westie implied, if there is one chartist that people can trust and respect, it's marnewton. I often wish that I had followed his guidance in the past.

[spike_1] 03/11/2016 09:14

Whether it was a waste of money depends on what Opti have to say at the conference:

The results of these studies (see below) will be presented at a Microbiome Summit in November 2016 and in a number of publications in mainstream scientific journals at the start of 2017.

1. Demonstration in human gut models of the ability of its microbiome modulators to increase the growth rate of specific microbial species in the human microbiome. This has now been demonstrated in multiple species, including OptiBiotix's cholesterol reducing strain (LP-LDL (TM) )

2. Demonstration in human gut models of the ability of its microbiome modulators to enhance a biological effect, such as cholesterol reduction. In the presence of microbiome modulators, OptiBiotix's cholesterol reducing strain (LP-LDL (TM) ) showed a threefold increase in cholesterol reduction

OptiBiotix believes that this is the first time that anyone has demonstrated a targeted change in the microbiome leading to an enhanced biological activity and improved health benefit (cholesterol reduction). This creates the opportunity for: -

1. Designer ingredients or supplements which can modify an individual's current microbiome to improve health

2. Combining microbiome modulators with existing products such as probiotics, a market that is expected to be worth more than $46.5bn by 2020 (Markets and Markets)

The results of these studies will be presented at a Microbiome Summit in November 2016 and in a number of publications in mainstream scientific journals at the start of 2017.

Best wishes - Mike

[1bokke] 03/11/2016 08:48

This line in the rns suggests the release was a targeted one..The conference is credited for attracting leading research scientists, leading companies in the industry and well connected investment groups, and is a good opportunity to network with like-minded individuals.

[scotty1] 03/11/2016 08:32

Cannot for the life of me see the point in putting that RNS out when the presentation was widely known,what a waste of money and time.

[dlku] 03/11/2016 07:54

filling the screen with non news RNS
Ramptastic

[judijudi] 03/11/2016 07:19

Let's hope the data they present will light the blue touch paper and make those on the sidelines jump aboard
Presumeably the data will good or why go to the trouble to present it
Could be on our way :)

[judijudi] 03/11/2016 07:15

Absolutely

[f3rdinand] 03/11/2016 07:06

RNS...Let's hope there are loads of those 'well connected investment groups' attending today and ready to splash out a few million on OPTI shares :)

[f3rdinand] 03/11/2016 06:39

Although I don't believe charts are much use on AIM shares I applaud those that provide them as they provide another tool for investment decisions.I think some times charts are a self-fulfilling prophecy... "Oh dear the support has gone...better sell up," when actually there is no reason to fundamentally! Each to their own....just because I don't follow them doesn't make me any more of an idiot that someone that does and sells out a day before a company changing RNS!

[bobdown2] 03/11/2016 05:58

For someone who cannot chart then it is a shame when the idiots have to show why they are idiots...the charting is excellent and should be treated as bonus..

[neftanikoff] 02/11/2016 23:57

post 17116 did amuse me, so much so that i have given you marnewton a tick up.
I, also am not an admirer of the sort of poster that JJ portrays. You do well to filter such creatures of the dark.
Keep up the chart analysis, your post's are quite interesting unlike those of JJ and her/his supporters.

[marnewton] 02/11/2016 23:36

Half as much volume today as yesterday and yet we remain on, rather than below, the 50 day SMA - that's two days on the trot. Nevertheless, the average can't be construed as support until it turns up...

I remain optimistic and will remain so above the 8 day ESA (currently 68.15p), but won't be happy until we have a couple of higher closes; by that I mean above 72.65p.


Hi westie, you're a gent, and a much more a decent guy than myself - I'm a grump!

As for JJ, he's been on filter for years and years. I found him to be "vexatious to the spirit" - with apologies to Desiderata.

I'm much amused by the way he pops up after my posts, presumably with his one-line snipes.

ATB

Martin

[westmoreland lad] 02/11/2016 22:40

Judi + F3rdinand -- re. All this talk of charts is meaningless imo.

Disagree F3rd. Followed Martin with his charts on several BBs over many years and have to say that in the main they have predicted the future. I accept we are in an AIM casino in some cases and where charts etc. could not possibly work but Martin puts his graphs up where applicable and is more often on the money than not.

Go easy on him JJ -- decent guy and been around ADVFN longer than most.

[mazzstar] 02/11/2016 21:29

Article today on fortune.com: "Why Gut Bacteria Are Having a Moment" There’s big money to be had in gut bacteria. Funding going toward companies related to the microbiome—the trillions of bacteria that live primarily in our digestive system—increased more than 400% between 2011 and 2015 and was up this year despite overall venture funding being down. Those were the stats Fortune senior writer Michal Lev-Ram cited to kick off a session on the so-called second brain. What’s in part driving the investment is a broader movement within healthcare as “people are taking much more control of their health,” said Jessica Richman, co-founder and CEO of startup uBiome at Fortune’s Brainstorm Health summit on Wednesday...Julie Smolyansky, president and CEO of Lifeway Foods, said that research is only now confirming the long-held assumptions that good bacteria lead to good health and longevity. “Right now the science is catching up to the folklore,” she said. “Our gut is controlling our entire body. We’re actually starting to understand we have a second brain in the gut.” Lifeway makes a fermented yogurt-like drink called kefir that contains probiotics—bacteria this is thought to promote good gut health. Smolyansky said her company is rolling out a probiotic in pill form as well.
Link: hxxp://fortune.com/2016/11/02/gut-bacteria-microbiome-investment/

[f3rdinand] 02/11/2016 19:41

I think you've just asked him for me! :)

[diamond fibre] 02/11/2016 17:42

What is this wild raspberry Keytone, that suppose to make you lose weight?